Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals Incorporated (VRTX), headquartered ... Ahead of the event, analysts expect Vertex to report a profit of $3.41 per share on a diluted basis, down 4.5% from $3.57 per share ...
Vertex Pharmaceuticals stock was heading for a ... 12% in one trading session after an element from a clinical trial report disappointed investors. Meanwhile, Vertex is heading for two pieces ...
Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a ...
Also, high R&D expenses on advanced technologies ... (You can read the full research report on Vertex Pharmaceuticals here >>>) Shares of BK Technologies have outperformed the Zacks Wireless ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback